Black Diamond Therapeutics Inc
NASDAQ:BDTX

Watchlist Manager
Black Diamond Therapeutics Inc Logo
Black Diamond Therapeutics Inc
NASDAQ:BDTX
Watchlist
Price: 2.61 USD -1.51%
Market Cap: $148.7m

Operating Margin

17.3%
Current
Improving
by 10.8%
vs 3-y average of 6.6%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
17.3%
=
Operating Income
$12.1m
/
Revenue
$70m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
17.3%
=
Operating Income
$12.1m
/
Revenue
$70m

Peer Comparison

Country Company Market Cap Operating
Margin
US
Black Diamond Therapeutics Inc
NASDAQ:BDTX
148.6m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
385B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
185.1B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
167.9B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.8B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.8B USD
Loading...

Market Distribution

Higher than 75% of companies in the United States of America
Percentile
75th
Based on 14 112 companies
75th percentile
17.3%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Black Diamond Therapeutics Inc
Glance View

Market Cap
148.7m USD
Industry
Biotechnology

Black Diamond Therapeutics, Inc. is a precision oncology medicine company, which engages in discovery and development of small molecule, masterkey therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 88 full-time employees. The company went IPO on 2020-01-30. The firm is focused on the discovery and development of small molecule, MasterKey therapies. The Company’s technology platform, Mutation-Allostery-Pharmacology (MAP) platform, is designed to allow it to analyze population-level genetic sequencing data to discover oncogenic mutations that promote cancer across tumor types. Its lead product candidate, BDTX-189, is designed as an orally available, irreversible small molecule inhibitor that targets a spectrum of 48 non-canonical and canonical driver mutations of the ErbB kinases epidermal growth factor receptor (EGFR) and HER2. BDTX-1535 is designed as a brain-penetrant small molecule inhibitor that targets a spectrum of EGFR mutations, including allosteric and canonical mutations. The company also has early-stage programs, such as B-Raf Proto-Oncogene (BRAF), and fibroblast growth factor receptor (FGFR).

BDTX Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
17.3%
=
Operating Income
$12.1m
/
Revenue
$70m
What is Black Diamond Therapeutics Inc's current Operating Margin?

The current Operating Margin for Black Diamond Therapeutics Inc is 17.3%, which is above its 3-year median of 6.6%.

How has Operating Margin changed over time?

Over the last 6 months, Black Diamond Therapeutics Inc’s Operating Margin has increased from -5% to 17.3%. During this period, it reached a low of -5% on Mar 31, 2025 and a high of 17.3% on Oct 30, 2025.

Back to Top